Study finds a majority of new drug approvals subject to PREA requirements have ongoing postmarketing studies
Regulatory NewsJeff Craven
Biologics/ biosimilars/ vaccinesClinical TrialsExpedited pathwaysPediatric productsPharmaceuticalsUnited StatesRegulatory NewsJeff CravenBiologics/ biosimilars/ vaccinesClinical TrialsExpedited pathwaysPediatric productsPharmaceuticalsUnited States